AR037677A1 - Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-1(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas. - Google Patents

Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-1(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.

Info

Publication number
AR037677A1
AR037677A1 ARP020104558A ARP020104558A AR037677A1 AR 037677 A1 AR037677 A1 AR 037677A1 AR P020104558 A ARP020104558 A AR P020104558A AR P020104558 A ARP020104558 A AR P020104558A AR 037677 A1 AR037677 A1 AR 037677A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
same
triazatetraciclo
pentaene
hexadeca
Prior art date
Application number
ARP020104558A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037677A1 publication Critical patent/AR037677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a las sales succinato de 5,8,13-triazatetraciclo[9,3,1.02,10.04,8]-pentadeca-2(10),3,5,8-tetraeno como en fórmula (1) y las composiciones farmacéuticas de las mismas. Se une a sitios específicos del receptor nicotínico neuronal de acetilcolina y es útil para modular la función colinérgica.
ARP020104558A 2001-11-29 2002-11-27 Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-1(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas. AR037677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33424501P 2001-11-29 2001-11-29

Publications (1)

Publication Number Publication Date
AR037677A1 true AR037677A1 (es) 2004-12-01

Family

ID=23306297

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104558A AR037677A1 (es) 2001-11-29 2002-11-27 Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-1(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.

Country Status (26)

Country Link
US (1) US6794388B2 (es)
EP (1) EP1461040B1 (es)
JP (1) JP4196829B2 (es)
KR (1) KR20040066140A (es)
CN (1) CN1589148A (es)
AR (1) AR037677A1 (es)
AT (1) ATE320256T1 (es)
AU (1) AU2002341327A1 (es)
BR (1) BR0214559A (es)
CA (1) CA2468705A1 (es)
DE (1) DE60209929T2 (es)
DO (1) DOP2002000512A (es)
ES (1) ES2258652T3 (es)
GT (1) GT200200236A (es)
HN (1) HN2002000332A (es)
IL (1) IL161326A0 (es)
MX (1) MXPA04003192A (es)
PA (1) PA8559401A1 (es)
PE (1) PE20030738A1 (es)
PL (1) PL374325A1 (es)
RU (1) RU2004116311A (es)
SV (1) SV2004001413A (es)
TW (1) TW200300345A (es)
UY (1) UY27548A1 (es)
WO (1) WO2003045394A1 (es)
ZA (1) ZA200402720B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
RU2317295C1 (ru) * 2003-10-27 2008-02-20 Мерк Энд Ко., Инк. Соль антагониста ccr-2
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
KR100734147B1 (ko) * 2005-07-29 2007-07-02 주식회사 엘지데이콤 호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법
US20090258840A1 (en) * 2006-05-16 2009-10-15 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
MX2009005043A (es) * 2006-11-09 2009-05-25 Pfizer Prod Inc Polimorfos de intermedios nicotinicos.
DK2125786T3 (da) * 2006-12-21 2011-05-09 Pfizer Prod Inc Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
PT2307435E (pt) * 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
PT2376499E (pt) * 2008-12-11 2015-06-03 Cti Biopharma Corp Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa- 5,7,26-triaza-tetraciclo[19.3.1.1(2,6)1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,1 (27),16,21,23-decaeno
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
CN104334561B (zh) 2012-04-13 2016-06-22 连云港金康和信药业有限公司 化合物jk12a及其制备
IL251769B (en) 2014-10-20 2022-06-01 Oyster Point Pharma Inc Varnicline compound for use as a drug for treating dry eye, increasing tear production and treating eye discomfort and a premebacte preparation containing Varnicline
TW202320785A (zh) 2016-04-07 2023-06-01 美商奧伊斯特普安生物製藥公司 治療眼部病狀之方法
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
ATE376838T1 (de) 1999-08-27 2007-11-15 Inex Pharmaceuticals Corp Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica

Also Published As

Publication number Publication date
ATE320256T1 (de) 2006-04-15
HN2002000332A (es) 2003-12-11
UY27548A1 (es) 2003-06-30
US20030149044A1 (en) 2003-08-07
MXPA04003192A (es) 2004-07-27
EP1461040A1 (en) 2004-09-29
CN1589148A (zh) 2005-03-02
JP2005513032A (ja) 2005-05-12
US6794388B2 (en) 2004-09-21
TW200300345A (en) 2003-06-01
KR20040066140A (ko) 2004-07-23
WO2003045394A1 (en) 2003-06-05
PA8559401A1 (es) 2004-02-07
EP1461040B1 (en) 2006-03-15
DE60209929D1 (de) 2006-05-11
CA2468705A1 (en) 2003-06-05
ZA200402720B (en) 2005-05-18
BR0214559A (pt) 2007-03-13
ES2258652T3 (es) 2006-09-01
IL161326A0 (en) 2004-09-27
RU2004116311A (ru) 2005-03-27
JP4196829B2 (ja) 2008-12-17
DE60209929T2 (de) 2006-11-16
AU2002341327A1 (en) 2003-06-10
SV2004001413A (es) 2004-05-07
PL374325A1 (en) 2005-10-17
DOP2002000512A (es) 2003-05-31
GT200200236A (es) 2003-06-25
PE20030738A1 (es) 2003-08-28

Similar Documents

Publication Publication Date Title
AR037677A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-1(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
ECSP055621A (es) Aza-biciclo-alquil-éteres y su uso como agonistas de alfa7-nachr
NZ504482A (en) Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
BRPI0408347A (pt) derivados de pirimidina
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
BRPI0316732B8 (pt) composto derivado de 3-aminopirrolidina e sua composição farmacêutica
BR0313880A (pt) composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
ATE411285T1 (de) Prolin-derivate und deren verwendung als medikamente
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
BRPI0513677A (pt) derivados de pirrol com agentes farmacêuticos
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ATE221064T1 (de) Cyclische amidderivate als neurokinin a antagonisten
BR0212069A (pt) Agentes antidiabéticos orais
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
ATE450262T1 (de) Harnstoff-derivate als calcium-rezeptor- modulatoren
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia

Legal Events

Date Code Title Description
FB Suspension of granting procedure